Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 8/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.88 |
| ▸ | TSHR | P16473 | 4/20 | 0.82 |
| ▸ | RECQL | P46063 | 2/20 | 0.82 |
| ▸ | MAPT | P10636 | 2/20 | 0.71 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | PKM | P14618 | 1/20 | 0.71 |
| ▸ | RAB9A | P51151 | 1/20 | 0.71 |
| ▸ | MAOB | P27338 | 2/20 | 0.69 |
| ▸ | GAA | P10253 | 1/20 | 0.66 |
| ▸ | GFER | P55789 | 1/20 | 0.66 |
| ▸ | LMNA | P02545 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14140751 | 1.00 | HPGD (1.00) | HPGDCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL244547 | 1.00 | HPGD (1.00) | HPGDCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL5970063 | 0.98 | HPGD (1.00) | HPGDCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL108225 | 0.92 | ALDH1A1 (0.90) | HPGDCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL244490 | 0.90 | HPGD (1.00) | HPGDCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7464300 | 0.84 | HPGD (0.75) | HPGDCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7433458 | 0.84 | HPGD (0.75) | HPGDCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8475795 | 0.83 | HPGD (0.71) | HPGDCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL93930 | 0.83 | ALDH1A1 (0.76) | HPGDCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL23675311 | 0.83 | HPGD (0.69) | HPGDCYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | UNIV CASE WESTERN RESERVE (US) | 2017-07-27 | — | — | US | disclosed |
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | UNIV CASE WESTERN RESERVE (US) | 2017-07-27 | — | — | US | disclosed |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2010-02-11 | — | — | US | disclosed |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR NIH | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170209425-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NTRK2, BDNF, NGF | HPGD 3434/4885CYP1A2 4878/4885CYP3A4 4881/4885 |
| US-20100035877-A1 | METHODS AND COMPOSITIONS FOR TREATING PATHOLOGIES ASSOCIATED WITH BDNF SIGNALING | NTRK2, NGF, BDNF | HPGD 2739/4885CYP1A2 4877/4885CYP3A4 4882/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.